Top-Rated Stocks NASDAQ:NTRA Natera - NTRA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Natera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $55.00 -0.99 (-1.77%) (As of 03/28/2023 11:15 AM ET) Add Compare Share Share Today's Range$54.82▼$55.8950-Day Range$39.72▼$58.2952-Week Range$27.35▼$59.75Volume189,505 shsAverage Volume1.41 million shsMarket Capitalization$6.23 billionP/E RatioN/ADividend YieldN/APrice Target$79.27 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Natera MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside41.6% Upside$79.27 Price TargetShort InterestHealthy5.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.32Based on 16 Articles This WeekInsider TradingSelling Shares$9.22 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.22) to ($2.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector342nd out of 1,002 stocksMedical Laboratories Industry13th out of 26 stocks 3.5 Analyst's Opinion Consensus RatingNatera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.27, Natera has a forecasted upside of 41.6% from its current price of $55.99.Amount of Analyst CoverageNatera has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.33% of the outstanding shares of Natera have been sold short.Short Interest Ratio / Days to CoverNatera has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Natera has recently decreased by 13.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNatera does not currently pay a dividend.Dividend GrowthNatera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NTRA. Previous Next 2.0 News and Social Media Coverage News SentimentNatera has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Natera this week, compared to 4 articles on an average week.Search Interest20 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows7 people have added Natera to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,221,887.00 in company stock.Percentage Held by Insiders10.27% of the stock of Natera is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.81% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Natera are expected to grow in the coming year, from ($4.22) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Natera is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Natera is -10.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNatera has a P/B Ratio of 7.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Natera (NASDAQ:NTRA) StockNatera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.Read More Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRA Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comMichael Burkes Brophy Sells 651 Shares of Natera, Inc. (NASDAQ:NTRA) StockMarch 26, 2023 | americanbankingnews.comMatthew Rabinowitz Sells 2,484 Shares of Natera, Inc. (NASDAQ:NTRA) StockMarch 28, 2023 | Press Research (Ad)Nevada Could be the Source for America's Green FutureIndustry shift towards lithium driven by green energy goalsMarch 26, 2023 | americanbankingnews.comMichael Burkes Brophy Sells 1,373 Shares of Natera, Inc. (NASDAQ:NTRA) StockMarch 25, 2023 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 1,656 SharesMarch 25, 2023 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 1,259 Shares of StockMarch 25, 2023 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 4,736 SharesMarch 25, 2023 | americanbankingnews.comNatera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Moderate Buy" from AnalystsMarch 28, 2023 | Press Research (Ad)Lithium Could Be 2023's Next Big SurpriseLithium is the hottest commodity for our green futureMarch 22, 2023 | businesswire.comNew Publication Demonstrates Utility of Natera’s Signatera™ Test in MelanomaMarch 2, 2023 | finance.yahoo.comNatera Announces Commercial Payor Coverage for Signatera™February 23, 2023 | finance.yahoo.comNatera Appoints Ruth E. Williams-Brinkley to its Board of DirectorsFebruary 21, 2023 | finance.yahoo.comNatera Announces Fourth Quarter and Fiscal 2022 Earnings Conference CallFebruary 16, 2023 | finance.yahoo.comMedicare Extends Coverage of Natera’s Signatera™ MRD Test to Breast CancerFebruary 4, 2023 | finance.yahoo.comNatera's (NASDAQ:NTRA) investors will be pleased with their fantastic 394% return over the last five yearsFebruary 3, 2023 | wsj.comNew Paper Highlights Clinical Utility of Natera's Renasight(TM) Test in the Management of Kidney DiseaseFebruary 2, 2023 | finance.yahoo.comNew Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney DiseaseJanuary 19, 2023 | finance.yahoo.comNew Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023January 17, 2023 | finance.yahoo.comNatera Announces Publication of Prospective, Multi-Site CIRCULATE Study in Nature Medicine Demonstrating Signatera’s Ability to Predict Chemotherapy Benefit in Colorectal CancerJanuary 12, 2023 | finance.yahoo.comWall Street Analysts Think Natera (NTRA) Could Surge 82.88%: Read This Before Placing a BetJanuary 3, 2023 | finance.yahoo.comNatera to Webcast Live Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.comA Natera, Inc. (NASDAQ:NTRA) insider increased their holdings by 13% last yearDecember 22, 2022 | finance.yahoo.comNatera Supports Updated ISHLT Guidelines for the Care of Heart Transplant PatientsDecember 9, 2022 | finance.yahoo.comNatera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric CancersDecember 7, 2022 | finance.yahoo.comNatera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer SymposiumDecember 7, 2022 | finance.yahoo.comAfter losing 58% in the past year, Natera, Inc. (NASDAQ:NTRA) institutional owners must be relieved by the recent gainDecember 6, 2022 | finance.yahoo.comNatera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPTSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter. Email Address NTRA Company Calendar Last Earnings2/28/2023Today3/28/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTRA CUSIPN/A CIK1604821 Webwww.natera.com Phone(650) 249-9090FaxN/AEmployees3,018Year FoundedN/APrice Target and Rating Average Stock Price Forecast$79.27 High Stock Price Forecast$100.00 Low Stock Price Forecast$65.00 Forecasted Upside/Downside+41.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($5.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-547,800,000.00 Net Margins-66.79% Pretax Margin-66.67% Return on Equity-106.67% Return on Assets-47.48% Debt Debt-to-Equity Ratio0.40 Current Ratio3.90 Quick Ratio3.79 Sales & Book Value Annual Sales$820.22 million Price / Sales7.73 Cash FlowN/A Price / Cash FlowN/A Book Value$7.23 per share Price / Book7.74Miscellaneous Outstanding Shares113,290,000Free Float101,652,000Market Cap$6.34 billion OptionableOptionable Beta1.20 Key ExecutivesStephen ChapmanPresident, Chief Executive Officer & DirectorRobert A. SchuerenChief Operating OfficerMichael Burkes BrophyChief Financial & Accounting OfficerEric A. EvansChief Scientific OfficerRishi KackerChief Technology OfficerKey CompetitorsGuardant HealthNASDAQ:GHExact SciencesNASDAQ:EXASQuest DiagnosticsNYSE:DGXLaboratory Co. of AmericaNYSE:LHAcadia HealthcareNASDAQ:ACHCView All CompetitorsInsiders & InstitutionsSteven Leonard ChapmanSold 1,656 sharesTotal: $91,229.04 ($55.09/share)Michael Burkes BrophySold 651 sharesTotal: $35,935.20 ($55.20/share)MetLife Investment Management LLCBought 531 shares on 3/23/2023Ownership: 0.005%Matthew RabinowitzSold 2,484 sharesTotal: $139,898.88 ($56.32/share)Steven Leonard ChapmanSold 4,736 sharesTotal: $266,731.52 ($56.32/share)View All Insider TransactionsView All Institutional Transactions NTRA Stock - Frequently Asked Questions Should I buy or sell Natera stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTRA shares. View NTRA analyst ratings or view top-rated stocks. What is Natera's stock price forecast for 2023? 6 Wall Street analysts have issued 12 month target prices for Natera's stock. Their NTRA share price forecasts range from $65.00 to $100.00. On average, they anticipate the company's share price to reach $79.27 in the next year. This suggests a possible upside of 41.6% from the stock's current price. View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts. How have NTRA shares performed in 2023? Natera's stock was trading at $40.17 at the start of the year. Since then, NTRA stock has increased by 39.4% and is now trading at $55.99. View the best growth stocks for 2023 here. When is Natera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our NTRA earnings forecast. How were Natera's earnings last quarter? Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings data on Tuesday, February, 28th. The medical research company reported ($1.37) earnings per share for the quarter, topping analysts' consensus estimates of ($1.40) by $0.03. The medical research company had revenue of $217.30 million for the quarter, compared to analyst estimates of $215.50 million. Natera had a negative net margin of 66.79% and a negative trailing twelve-month return on equity of 106.67%. The company's revenue was up 25.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.48) earnings per share. What ETFs hold Natera's stock? ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger Mid Cap 40 ETF (FRTY), Alger 35 ETF (ATFV), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), Principal Healthcare Innovators ETF (BTEC), VanEck Biotech ETF (BBH) and SPDR S&P Biotech ETF (XBI). What guidance has Natera issued on next quarter's earnings? Natera updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $980.00M-$1.00 billion, compared to the consensus revenue estimate of $988.88 million. What is Steve Chapman's approval rating as Natera's CEO? 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Natera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN). When did Natera IPO? (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers. What is Natera's stock symbol? Natera trades on the NASDAQ under the ticker symbol "NTRA." Who are Natera's major shareholders? Natera's stock is owned by many different retail and institutional investors. Top institutional investors include Fred Alger Management LLC (9.19%), Norges Bank (2.85%), Eversept Partners LP (2.75%), Principal Financial Group Inc. (2.06%), Avidity Partners Management LP (1.84%) and Braidwell LP (1.66%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens. View institutional ownership trends. How do I buy shares of Natera? Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Natera's stock price today? One share of NTRA stock can currently be purchased for approximately $55.99. How much money does Natera make? Natera (NASDAQ:NTRA) has a market capitalization of $6.34 billion and generates $820.22 million in revenue each year. The medical research company earns $-547,800,000.00 in net income (profit) each year or ($5.57) on an earnings per share basis. How many employees does Natera have? The company employs 3,018 workers across the globe. How can I contact Natera? Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com. This page (NASDAQ:NTRA) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.